However, there is encouraging work in sepsis, comparable to the enrichment strategies of certain immune or targeted therapies in oncology, based on evaluation of biomarkers, for example sTREM-1, bio-adrenomedullin, or monocyte expression of HLA-DR associated with particular pathophysiological mechanisms occurring in some sepsis patients [80–82]. This evidence concerns the gene ADM and Sepsis.